Study summary

Tezepelumab met both main goals in eosinophilic esophagitis

CROSSING trial · 368 people, phase 3 · Topline August 2026

What was tested

Tezepelumab (Tezspire), an antibody blocking TSLP, against placebo in adolescents and adults with eosinophilic esophagitis.

What they found

Met both tissue remission and swallowing goals at week 24, sustained through week 52.

What it means

Already approved for severe asthma and nasal polyps; a filing for EoE is expected.

Amgen press release ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.